Abstract
Extending on recent progress in control of matter at the nanoscale, functional nanoparticles and drug nanocarriers are being actively developed with the promise of improved delivery of therapeutic agents. Nanotechnology-enabled drug delivery approaches usually aim at reducing the systemic distribution and associated side-effects typically observed with conventional chemotherapeutic molecules as well as increasing the therapeutic index of the active agents. The enhanced permeation and retention effect has been exploited with notable success to passively deliver nanostructured drug carriers and therapeutic nanoparticles in vivo. Strategies aimed at further enhancing the nanocarriers accumulation within tumor tissues are under intensive investigation and could enable, in a not too distant future, the realization of the long sought after goal of chemotherapy without – or with reduced - side-effects. In particular, immunotargeted approaches are widely predicted to offer much greater specificity towards the target cells and tissues. Advancement in molecular biology has indeed made a wealth of information available in biological processes and application of this new knowledge to nanostructured agents, has also generated unprecedented hope of novel molecular diagnostic and therapeutic strategies. Focusing on oncological applications, this review aims to discuss the recent developments in immunotargeting of functional nanoparticles and drug nanocarriers and the integration of these systems into clinically relevant therapeutic applications.
Keywords: Nanocarriers, drug delivery, targeting, immunotargeting, cancer, therapy
Current Drug Delivery
Title: Drug Nanocarriers and Functional Nanoparticles: Applications in Cancer Therapy
Volume: 6 Issue: 4
Author(s): Benjamin Thierry
Affiliation:
Keywords: Nanocarriers, drug delivery, targeting, immunotargeting, cancer, therapy
Abstract: Extending on recent progress in control of matter at the nanoscale, functional nanoparticles and drug nanocarriers are being actively developed with the promise of improved delivery of therapeutic agents. Nanotechnology-enabled drug delivery approaches usually aim at reducing the systemic distribution and associated side-effects typically observed with conventional chemotherapeutic molecules as well as increasing the therapeutic index of the active agents. The enhanced permeation and retention effect has been exploited with notable success to passively deliver nanostructured drug carriers and therapeutic nanoparticles in vivo. Strategies aimed at further enhancing the nanocarriers accumulation within tumor tissues are under intensive investigation and could enable, in a not too distant future, the realization of the long sought after goal of chemotherapy without – or with reduced - side-effects. In particular, immunotargeted approaches are widely predicted to offer much greater specificity towards the target cells and tissues. Advancement in molecular biology has indeed made a wealth of information available in biological processes and application of this new knowledge to nanostructured agents, has also generated unprecedented hope of novel molecular diagnostic and therapeutic strategies. Focusing on oncological applications, this review aims to discuss the recent developments in immunotargeting of functional nanoparticles and drug nanocarriers and the integration of these systems into clinically relevant therapeutic applications.
Export Options
About this article
Cite this article as:
Thierry Benjamin, Drug Nanocarriers and Functional Nanoparticles: Applications in Cancer Therapy, Current Drug Delivery 2009; 6 (4) . https://dx.doi.org/10.2174/156720109789000474
DOI https://dx.doi.org/10.2174/156720109789000474 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot Topic:Recent Advances in Molecular Targeting of Head and Neck Cancer (Guest Editor: Dong Moon Shin, M.D.)]
Current Cancer Drug Targets Ligand-Based Drug Design of Novel MARK-3 Inhibitors in Cancer
Current Bioactive Compounds Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Radiolabeled Compounds in the Development of Cytotoxic Agents
Current Pharmaceutical Design Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Association Between miR-146a rs2910164 Polymorphism and Breast Cancer Susceptibility: An Updated Meta-Analysis of 9545 Cases and 10030 Controls
MicroRNA Design, Synthesis and Antitumor Activity of Quinazoline Derivatives Bearing 2,3-Dihydro-indole or 1,2,3,4-Tetrahydroquinoline
Letters in Drug Design & Discovery Epoch-making Treatment with Transoral Robotic Surgery for Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Current Medicinal Chemistry Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism Medical Image Processing Technology for Diagnosing and Treating Cancers
Recent Patents on Biomedical Engineering (Discontinued) Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology